Last updated: 16 November 2021 at 4:45pm EST

Roderick Carter Net Worth



Roderick Carter biography

Dr. Roderick Carter is Executive Chairman of the Board of the company. Carter held various commercial and research leadership roles including Merck and Pfizer. He was vice-president of clinical development at Reliant Pharmaceuticals, which developed the omega-3 cardiovascular drug Lovaza and today is a wholly owned subsidiary of GlaxoSmithKline.



What's Roderick Carter's mailing address?

Roderick's mailing address filed with the SEC is C/O ACASTI PHARMA INC., 3009 BOUL. DE LA CONCORDE, SUITE 102, LAVAL, A6, H7E 2B5.

Insiders trading at Acasti Pharma Inc

Over the last 3 years, insiders at Acasti Pharma Inc have traded over $0 worth of Acasti Pharma Inc stock and bought 676,752 units worth $1,252,067 . The most active insiders traders include Vimal Kavuru, John Canan et R. Loch Macdonald. On average, Acasti Pharma Inc executives and independent directors trade stock every 13 days with the average trade being worth of $785,032. The most recent stock trade was executed by Vimal Kavuru on 25 September 2023, trading 676,371 units of ACST stock currently worth $1,251,286.



What does Acasti Pharma Inc do?

acasti pharma, inc., a subsiduary of neptune technologies & bioressources, is a quebec-based biopharmaceutical dedicated in advancing a proprietary portfolio based on marine phospholipids. our products can be used in prescription, medical food and over-the-counter applications, either as a stand-alone, or, as a fixed-dose combination to exisitng productrs, for the prevention and treatment of cardiometabolic disorders.



What does Acasti Pharma Inc's logo look like?

Acasti Pharma Inc logo

Acasti Pharma Inc executives and stock owners

Acasti Pharma Inc executives and other stock owners filed with the SEC include: